Skip to main content

Month: May 2024

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:Date: June 5, 2024   Time: 4:30 ET   Webcast: Click Here   To schedule a 1×1 meeting with the Company, please contact your Jefferies representative. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business...

Continue reading

OTTAWA BANCORP, INC. APPROVES STOCK REPURCHASE PROGRAM

OTTAWA, Ill., May 29, 2024 (GLOBE NEWSWIRE) — Ottawa Bancorp, Inc. (OTCQX: OTTW) (the “Company”), the holding company for OSB Community Bank (the “Bank”), announced today that the Company’s Board of Directors has approved a stock repurchase program authorizing the repurchase of 127,332 shares, or 5%, of the Company’s outstanding common stock. Stock repurchases will be conducted through open market purchases, which will include purchases under a trading plan adopted pursuant to Securities and Exchange Commission Rule 10b5-1, or through privately negotiated transactions. Repurchases will be made from time to time depending on market conditions and other factors. The Company’s stock repurchase program will terminate upon the completion of the purchase of 127,332 shares or on February 10, 2025 if not all shares have been purchased...

Continue reading

Earth Alive highlights a strong first quarter in 2024

MONTREAL, May 29, 2024 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (TSXV: EAC – “Earth Alive” or the “Company”), a company that develops, manufactures and distributes state-of-the-art, environmentally-sound proprietary microbial solutions and products, is pleased to announced today its financial results for the first quarter ended March 31, 2024. All amounts are in Canadian dollars unless otherwise indicated. Highlights of the First QuarterSales totalled $1,301,021 in Q1 2024 compared to sales of $387,247 in Q1 2023 thanks to the acquisition of Interlube Inc. Total net loss of $1,333,569 compared to total net loss of $1,262,881 in Q1 2023 Total operating expenses of $1,552,451 compared to total operating expenses of $1,346,261 in Q1 2023 The working capital totaled $ 3,644,679 on March 31, 2024 with $2,013,090 in cash...

Continue reading

AMSC Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Outlook

Business Highlights:Full year revenues increased over 37% year over year to $145.6 million Full year gross margin expansion of 1,620 basis points over the prior year Generated $2.1 million of operating cash flow, helping to further strengthen the balance sheetCompany to host conference call tomorrow, May 30 at 10:00 am ET AYER, Mass., May 29, 2024 (GLOBE NEWSWIRE) — AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™, and that protect and expand the capability and resiliency of our Navy’s fleet, today reported financial results for its fourth quarter and fiscal year ended March 31, 2024 (“fiscal 2023”). Revenues for the fourth quarter of fiscal 2023 were $42.0 million compared with $31.7 million for the same...

Continue reading

HP Inc. Reports Fiscal 2024 Second Quarter Results

PALO ALTO, Calif., May 29, 2024 (GLOBE NEWSWIRE) — HP (NYSE: HPQ)Second quarter GAAP diluted net earnings per share (“EPS”) of $0.61, within the previously provided outlook of $0.58 to $0.68 per share Second quarter non-GAAP diluted net EPS of $0.82, within the previously provided outlook of $0.76 to $0.86 per share Second quarter net revenue of $12.8 billion, down 0.8% from the prior-year period Second quarter net cash provided by operating activities of $0.6 billion, free cash flow of $0.5 billion Second quarter returned $0.4 billion to shareholders in the form of dividends and share repurchases HP Inc.’s fiscal 2024 second quarter financial performance  Q2 FY24 Q2 FY23 Y/YGAAP net revenue ($B) $ 12.8   $ 12.9   (0.8)%GAAP operating margin   7.4%     5.8%   1.6 ptsGAAP net earnings ($B) $ 0.6   $ 1.1   (42)%GAAP...

Continue reading

Credo Technology Group Holding Ltd Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SAN JOSE, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Credo Technology Group Holding Ltd (Nasdaq: CRDO) (“Credo”), an innovator in providing secure, high-speed connectivity solutions that deliver improved energy efficiency, today reported financial results for the fourth quarter and full fiscal year 2024, ended April 27, 2024. Fourth Quarter of Fiscal Year 2024 Financial HighlightsRevenue of $60.8 million grew by 89.4% year over year GAAP gross margin of 65.8% and non-GAAP gross margin of 66.1%   GAAP operating expenses of $47.8 million and non-GAAP operating expenses of $32.7 million GAAP net loss of $10.5 million and non-GAAP net income of $11.8 million GAAP diluted net loss per share of $0.06 and non-GAAP diluted net income per share of $0.07 Ending cash and short-term investment balance of $410.0 millionManagement Commentary Bill...

Continue reading

nCino Reports First Quarter Fiscal Year 2025 Financial Results

• Total Revenues of $128.1M, up 13% year-over-year • Subscription Revenues of $110.4M, up 13% year-over-year • GAAP Operating Margin of (3)%, up ~500 basis points year-over-year • Non-GAAP Operating Margin of 19%, up ~900 basis points year-over-year WILMINGTON, N.C., May 29, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced financial results for the first quarter of fiscal year 2025, ended April 30, 2024. “Building on our fourth quarter momentum, we had a great start to the year, achieving our highest first-quarter gross sales in Company history,” said Pierre Naudé, Chairman and CEO at nCino. “Our strong sales execution produced wins across multiple markets, highlighting the breadth and depth of our product portfolio and the effectiveness...

Continue reading

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the batoclimab Myasthenia Gravis (MG) study is also expected over this fiscal year and further potentially registrational development in MG with IMVT-1402 is expected to begin in the same timeframe Immunovant has decided to run the batoclimab trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) longer prior to unblinding period 1 in order to better ensure that the data from the batoclimab trial, combined with learning from other CIDP trials, can be used to optimize the IMVT-1402 CIDP trial design  Detailed results from the batoclimab study in...

Continue reading

Nokia Corporation: Repurchase of own shares on 29.05.2024

Nokia CorporationStock Exchange Release29 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 29.05.2024 Espoo, Finland – On 29 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 429,773 3.50CEUX – –BATE – –AQEU – –TQEX – –Total 429,773 3.50* Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation...

Continue reading

VEON appoints UHY LLP as auditors for VEON Group’s 2023 PCAOB Audit and shares compliance plan with Nasdaq

Amsterdam, 29 May 2024 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, (“VEON” or the “Company” or, together with its subsidiaries, the “Group”), announces that it has appointed UHY LLP (UHY) as the independent registered public accounting firm for the audit of the Group’s consolidated financial statements for the year ended December 31, 2023 in accordance with the standards established by the Public Company Accounting Oversight Board (United States) (the “PCAOB Audit”).   As previously announced, VEON experienced a delay in filing its 2023 annual report on Form 20-F (the “2023 20-F”) due to the challenges it faced in connection with the timely appointment of an independent auditor that meets the requirements for a PCAOB audit following VEON’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.